Advertisement
Canada markets close in 31 minutes

  • S&P/TSX

    21,796.05
    +87.61 (+0.40%)
     

  • S&P 500

    4,969.23
    -41.89 (-0.84%)
     

  • DOW

    37,968.69
    +193.31 (+0.51%)
     

  • CAD/USD

    0.7273
    +0.0010 (+0.13%)
     

  • CRUDE OIL

    83.26
    +0.53 (+0.64%)
     

  • Bitcoin CAD

    88,453.70
    +1,331.97 (+1.53%)
     

  • CMC Crypto 200

    1,382.97
    +70.35 (+5.36%)
     

  • GOLD FUTURES

    2,410.10
    +12.10 (+0.50%)
     

  • RUSSELL 2000

    1,939.87
    -3.09 (-0.16%)
     

  • 10-Yr Bond

    4.6150
    -0.0320 (-0.69%)
     

  • NASDAQ

    15,291.85
    -309.65 (-1.98%)
     

  • VOLATILITY

    18.86
    +0.86 (+4.77%)
     

  • FTSE

    7,895.85
    +18.80 (+0.24%)
     

  • NIKKEI 225

    37,068.35
    -1,011.35 (-2.66%)
     

  • CAD/EUR

    0.6825
    +0.0004 (+0.06%)
     
MARKETS LIVE BLOG:

S&P 500 SLIPS BELOW 5,000; NASDAQ SINKS ON NETFLIX DRAG

Fed's Goolsbee says 'It makes sense to wait' before cutting rates

NervGen Pharma Grants Stock Options

Newsfile Corp.
·1 min read

Vancouver, British Columbia--(Newsfile Corp. - May 23, 2023) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that the Company has granted 400,000 incentive stock options to directors of the Company, exercisable at a price of $1.61 per share for a period of five years and that vest equally every three months over a one-year period. All options have been granted in accordance with the policies of the TSX Venture Exchange and the conditions of the Company's stock option plan.

About NervGen

NervGen is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The Company's initial target indications are spinal cord injury, Alzheimer's disease and multiple sclerosis. For more information, go to www.nervgen.com.

ADVERTISEMENT

For further information, please contact:

Huitt Tracey, Corporate Communications
htracey@nervgen.com
604.537.2094

Nancy Thompson, Vorticom Public Relations
nancyt@vorticom.com
212.532.2208

Follow NervGen on Twitter, LinkedIn, and Facebook for the latest news on the Company.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/167145